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Abstract
Traditionally, obesity has been viewed as a simple disease of excess calorific intake in the
context of a sedentary lifestyle. However, while an increase in energy consumption without
corresponding expenditure is a key force in the initial development of obesity, a number of
homeostatic mechanisms conspire to maintain high adiposity in individuals who are already
overweight. Both central neuronal mechanisms and peripheral endocrine signals drive
increased appetite and reduced metabolic rate in the obese. This prevents weight loss from
occurring as quickly as one would expect, and makes sustained weight loss of more than
15% almost impossible. Currently, the most effective therapy for obesity is bariatric surgery.
While previously believed to effect weight loss through malabsorption, restriction of
stomach capacity or both, it is now shown that these operations fundamentally change the
internal milieu of obese individuals, favouring weight loss and a reduction in appetite via
cumulative changes in neuroendocrine signalling. This has led to some exploration of
methods to directly affect the final common pathways in the brain and more efficiently
produce weight loss.
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Introduction
Obesity is fast becoming a global epidemic. For the first time in
human history, more people are dying as a result of relative
calorie excess than of calorie deficit.1 In developing nations,
obesity and malnutrition coexist to create a ‘double burden’ of
disease on already stretched health systems.2 The traditional
medical approach of prescribing increased exercise and reduced
calorie intake, although shown to produce modest, clinically
significant weight loss (usually around 5-10%), is often difficult
for patients to adhere to in the first instance3 and is prone to
recidivism. The interest this creates in pharmacological and
surgical means of treating obesity has resulted in greater
understanding of how our appetite is regulated.
Acquisition of calories and nutrients necessary for survival creates
a powerful selection pressure on an organism. Evolution has
thereby resulted in a complex homeostatic network in individual
organisms to regulate appetite and prevent acute changes in
adiposity.4 In humans, powerful neuroendocrine interplay exists
between the digestive system, which initially receives and absorbs
nutrients ingested by the organism, the adipose organ, a large
endocrine organ involved in both energy storage and
anorexigenic signalling, and the brain, the centre of behaviour.5
Greater understanding of the crosstalk between these three
systems is required in order to facilitate the treatment of the
obese patient, and ultimately to reduce the level of obesity and
its concomitant complications in the future.
The lipostat hypothesis
Despite our general tendency to get bigger when calories are no
object, individually mammals tend to ‘guard’ their weight. A
number of experiments illustrate this: animals were either overfed
or underfed for a relatively short time frame, then allowed an ad
libitum diet. The animals exhibited compensatory behavioural and
metabolic changes to restore their original weight, suggesting
that there is a sliding set point, which internally monitors weight
gain and loss and prevents drastic changes. This ‘lipostat’ is
situated – like many homeostatic regulatory centres – in the
hypothalamus.6
The lipostat purposefully integrates the peripheral signals of
dietary intake and the central signals of satiety, and translates
them into appropriate behavioural, metabolic and appetite
changes, which maintain weight at its typical level. This is
important from a homeostatic perspective: a 1% miscalculation
of calorific intake or expenditure (around 20kcal a day, equivalent
to a single serving of cabbage) would result in the accumulation
of an extra 1kg a year or >50kg over the average adult lifespan.4
It also means that once the set point has been driven upwards (as
in obesity), the lipostat modifies energy expenditure and calorie
intake to maintain our internally determined weight. Therefore,
the traditional medical mantra of ‘eat less, move more’ may not
be sufficient for long-term, meaningful weight loss in those who
are clinically overweight/obese.
Peripheral signals: signs of dietary intake
Three separate organs act as peripheral nutrient sensors to the
hypothalamic centres involved in appetite: the stomach/small
intestine, the pancreas and the adipose organ. Each contributes
either to acute appetite regulation (satiety following a meal) or
the long-term control of eating. Signals may be endocrine, neural
or neuroendocrine in nature, and can be produced by direct
sensing of the relevant constituents of food (e.g., fatty acids) or
by mechanotransduction (stretch of the viscera leading to
relevant hormone release or neural afferent firing).7 This gives the
central integrating regions of the brain a sense of the volume and
type of meal that has been ingested.
Signals from the periphery are almost all stimulated by dietary
intake. A variety of mechanisms highlight the complexity of
appetite regulation; the major determinants of satiety from the
periphery, however, are anorexigenic (stimulate feelings of
fullness).8
Anorexigenic (appetite-suppressing) signals
Simple neuronal mechanisms act via the vagus nerve. Stretch of
the stomach increases the rate of vagal afferent firing, which is
processed initially in the nucleus tractus solitarius before
projecting to the hypothalamus. As the stomach stretches and
mechanotransduction increases, the feeling of fullness increases
proportionally.8
Neuroendocrine mechanisms also increase the activity of the
vagus nerve, either via receptors (e.g., CCK1 receptors
responding to cholecystokinin and leading to increased vagal
afferent firing) or by increasing gastric stretch, such as the
reduction of intestinal motility by peptide tyrosine tyrosine (PYY).
The central role of the vagus nerve in communicating satiety
signals from the gut is underlined by evidence that vagotomies in
animal models often result in a loss of anorexigenic hormone
signalling, resulting in overfeeding and weight gain.9
Hormones also act centrally to produce feelings of satiety.
Glucagon-like peptide 1 (GLP-1), perhaps better known as an
incretin since the addition of exenatide to the pharmacopoeia for
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diabetes, has an important role in generating central satiety.
Delivery of GLP-1 antagonists centrally promoted overeating in
experimental rodent models;10 additionally, the SCALE study
recently illustrated that the GLP-1 analogue ‘liraglutide’ produced
meaningful weight loss as an adjunct to diet and exercise.11
Pancreatic peptide (PP) also acts centrally via Y4 receptors and
increases proportionally with the calorie content of ingested food
boluses.7
Two hormones increase proportionally with fat mass: insulin, a
pancreatic hormone secreted in response to food ingestion, and
leptin, an adipokine directly secreted from adipose tissue. These
hormones act as acute and chronic negative feedback loops.7
Mice lacking leptin (ob/ob) are indistinguishable from their
heterozygote littermates at birth, but quickly gain weight
through massive overeating. Rarely, human obesity has been
shown to be associated with a loss of leptin function; however, in
the vast majority of patients leptin is massively oversecreted.12
This has important implications for how the hormone is sensed
centrally and reduces the lipostat’s ability to appreciate total fat
mass.
Orexigenic signals
There is a single orexigenic signal secreted in the periphery:
ghrelin, a peptide secreted from the stomach, acts on its receptor
(GHS-R) to stimulate appetite. Ghrelin levels are highest while
fasting and are higher in individuals who are chronically fasted
(such as those with anorexia nervosa and people on weight loss
diets). Ghrelin acts throughout the gut–brain axis to increase
gastric motility, gastric acid secretion and calorific intake.7
Central signals: our hedonistic brain
The brain is the integrative centre of the whole organism, allowing
appropriate responses to both external and internal stimuli. Two
important groups of neurons have been identified: an orexigenic
group, Agouti-related peptide/neuropeptide Y neurons
(AgRP/NPY); and, an anorexigenic group, pro-opiomelanocortin
neurons (POMC). AgRP neurons are stimulated by ghrelin and
inhibited by PYY, leptin and insulin. In POMC neurons the inverse
is true.13 This bimodal system of antagonistic neurons integrates
peripheral signals, producing an appropriate feeling of hunger or
fullness. The result is a sensitive homeostatic sensor, which
monitors input and modulates output by multiple efferent
pathways, such as the paraventricular hypothalamus, dorsomedial
hypothalamic nucleus and the limbic system.14
This acts via a second order set of neurons to alter metabolism by
regulating thyroid hormone signalling, and behaviour via
efferents to higher cortical centres.15,16 The cortex also plays a
role, with modifications in taste, smell and memory, all driven by
activity in the arcuate nucleus and circulating appetite-regulating
hormones.17
Alterations in signalling in the obese patient
So why, in spite of such overwhelmingly complex homeostatic
machinery, do people become obese? As individuals gain fat
mass, levels of insulin and leptin secretion increase. As is seen in
type II diabetes mellitus (T2DM), high circulating levels of insulin
result in tissue becoming resistant to its effects, and failure of
peripheral tissues to uptake glucose.18 A similar process occurs in
the central nervous system in regards to leptin: as higher levels
accumulate in the blood, the brain ceases to respond
appropriately, negating leptin’s influence as a satiety signal.12
Subsequently, as patients increase their energy expenditure
(exercise) or reduce calorie intake (diet) in order to lose weight,
GLP-1, PYY and other anorexigenic hormones are suppressed in
favour of ghrelin secretion.3 This acts via central mechanisms,
resulting in changes in behaviour and metabolism that prevent
effective weight loss, making it difficult for patients to attain
sustained and clinically meaningful changes in fat mass.
Bariatric surgery: anatomical or biochemical
intervention?
An emerging therapy for obesity is bariatric surgery, particularly
the Roux-en-Y gastric bypass. This procedure was developed to
produce weight loss through restriction of total stomach volume
(producing earlier vagal stimulation by stretch) and
malabsorption.3 However, it has since come to light that this
mechanism alone is unlikely to result in the sustained weight loss
seen in patients postoperatively. Some 85% of patients with
T2DM became normoglycaemic following the procedure,
independent of weight loss. This suggests that some change is
elicited in hormonal signalling and, ultimately, the gut–brain
axis.19
Weight loss following a Roux-en-Y gastric bypass is dissimilar
physiologically from weight loss due to starvation, exercise or
dieting. With the traditional ‘eat less, move more’ paradigm,
ghrelin increases and GLP-1 and PYY decrease to create an
appetite-stimulating hormonal milieu. Following Roux-en-Y the
inverse is true.20 The chance of a person having a significant
response to Roux-en-Y bypass, or losing a clinically significant
amount of weight following surgery, can be predicted with some
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accuracy by measuring these hormones. Leptin is reduced to
levels comparable to lean subjects, indicating a return to a
non-obese hormone profile.17 Finally, non-specific inhibition of
hormone signalling with somatostatin allows for an increase in
appetite as tested by an ad libitum meal.21
Unfortunately, this surgery also carries the risk of developing
malabsorption and dumping syndromes; thus, it is only reserved
for individuals with very high BMIs (40kg/m2 without
comorbidities or 35kg/m2 with comorbidities).22,23 Evidence is
beginning to accumulate for a less drastic operation, the sleeve
gastrectomy, which carries a lower risk of mortality and morbidity
but also has a reduced chance of producing sustained weight loss
and a change in obesity-related disease.24
Deep brain stimulation: neuromodulation of a final
common pathway
While the hormonal control elicited by gastric bypass is
impressive, researchers are now considering how best to
manipulate the final common pathway of satiety. Deep brain
stimulation (DBS) is currently indicated for a number of diseases
(notably Parkinson’s disease) with impressive reductions in
symptoms.25 This intervention requires stereotactic placement of
electrodes in the brain (around the lateral hypothalamus), but
eliminates the risk of malabsorption.26 It is arguably more precise
than the Roux-en-Y by consistently affecting the final common
pathway.
Although research is only beginning in this intriguing approach
to a common illness, results are reasonably promising. A 2013
pilot study of bilateral implantation of DBS electrodes (developed
for Parkinson’s disease) into the lateral hypothalamic nuclei of
three patients with intractable obesity was performed safely and
had some evidence of efficacy. A major limiting factor of this
study was that the electrodes that are produced for Parkinson’s
neuromodulation are too large to target the specific areas of the
lateral hypothalamus associated with appetite;27 however, as the
technology develops, more success may emerge from this
approach to the treatment of obesity. Additionally, a wide range
of alternative targets is being explored – such as elements of the
brain’s reward circuitry (nucleus accumbens) – suggesting new
directions for the future of bariatric surgery.28
Conclusions
Obesity has historically been associated with poor health.
Hippocrates reportedly stated: “Corpulence is not only a disease
itself, but the harbinger of others”. In the modern era of energy-
(and calorie-) sparing devices for work and easy availability of
calorie-dense foods, a veritable epidemic of ‘corpulence’ has
emerged.29,30 While the best solution to this problem is
prevention, there will inevitably be individuals who gain enough
weight to endanger their health.
Medical treatment of obesity has historically been simplistic and
has neglected the complexity of human biology and the powerful
homeostatic mechanisms to prevent sudden changes in
physiology. Prescription of diet and exercise will continue to be
the mainstay of treatment in the overweight, but an awareness of
the limitations of this strategy is an important consideration for
clinicians.
Understanding the gut–brain axis also allows for tailoring
treatment of the obese patient in novel ways, by using GLP-1
agonists as an adjunct for weight loss or utilising surgery
(bariatric or neurological) to fundamentally alter the
communication pathways between these organs, as discussed
above. Ultimately, this will produce a range of therapies that are:
a) effective; and, b) enduring in the fight against obesity,
reducing patient morbidity and mortality, and allowing
individuals to lead healthier, happier and longer lives.
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